Ignite Creation Date:
2024-05-06 @ 10:34 AM
Last Modification Date:
2024-10-26 @ 12:32 PM
Study NCT ID:
NCT03297424
Status:
COMPLETED
Last Update Posted:
2022-07-25
First Post:
2017-09-08
Brief Title:
A Study of PLX2853 in Advanced Malignancies
Sponsor:
Opna Bio LLC
Organization:
Opna Bio LLC
Study Overview
Official Title:
A Phase 1b Dose-escalation Study to Assess Safety Pharmacokinetics Pharmacodynamics and Preliminary Efficacy of PLX2853 in Subjects With Advanced Malignancies
Status:
COMPLETED
Status Verified Date:
2022-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this research study is to evaluate safety pharmacokinetics pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with advanced malignancies
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None